RxDoctor Payments Data

Stephanie Bauer

Family · Chicago, ILNPI 1639285968

Payments from drug & device makers

$7,604in general payments, 2019–2025

Across 25 payments — averaging $304.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Incyte Corporation$2K
  • Autolus Inc$1K
  • Kadmon Pharmaceuticals LLC$952
  • AbbVie$420
  • E.r. Squibb & Sons, L.L.C.$295
  • plus $449 from 4 others

What the payments were for

  • Consulting fees$5,27369%
  • Speaking & faculty fees$1,29517%
  • Food & beverage$1,01713%
  • Education$190%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis5$2,517
Incyte Corporation4$1,675
Autolus Inc1$1,295
Kadmon Pharmaceuticals LLC1$952
AbbVie6$420
E.r. Squibb & Sons, L.L.C.2$295
Adaptive Biotechnologies Corporation3$277
Janssen Scientific Affairs, LLC1$94
Gilead1$48
Sanofi1$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,604 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$60,999
Medicare patients
84
Services billed
1,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate51$858,182
IclusigPonatinib Hcl11$193,457
VenclextaVenetoclax29$97,968
XareltoRivaroxaban20$12,800
EliquisApixaban21$12,416
Fluconazole37$3,791
Acyclovir67$1,454
Tacrolimus39$1,050
ValacyclovirValacyclovir Hcl32$791
Gabapentin28$483
Ciprofloxacin Hcl15$444
Acetazolamide ErAcetazolamide11$384
Pantoprazole Sodium26$363
Omeprazole25$338
MethotrexateMethotrexate Sodium20$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$1,675$858,18251 claims
AbbVieVenclexta$420$97,96829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →